Bevacizumab in Diffuse Midline Gliomas
Bevacizumab can be considered as a treatment option at recurrence in diffuse midline gliomas, though its impact on overall survival remains unproven and should be used primarily for symptom management rather than disease control. 1
Guideline-Based Framework
The 2021 EANO guidelines explicitly address K27M-mutant diffuse midline gliomas and state that "benefits from treatment options beyond radiotherapy have not been established because these tumours are rare and have not been studied in dedicated trials" 1. However, the guidelines acknowledge bevacizumab as an option for pharmacotherapy at recurrence in high-grade gliomas, with the critical caveat that "an impact on OS remains unproven" 1.
Key Clinical Context
Diffuse midline gliomas (particularly H3K27M-mutant) present unique challenges:
- Surgical options are severely limited due to anatomical location (brainstem, thalamus, spinal cord)
- MGMT promoter is usually unmethylated, limiting temozolomide efficacy
- Prognosis remains poor regardless of intervention 1
FDA Label Considerations
The FDA label for bevacizumab (Avastin) provides important safety context: bevacizumab showed no antitumor activity in pediatric patients with relapsed glioblastoma and failed to improve event-free survival in pediatric high-grade glioma trials (n=121) 2. This is particularly relevant since many diffuse midline gliomas occur in pediatric and young adult populations.
Evidence for Specific Clinical Scenarios
When Bevacizumab May Provide Benefit:
Symptomatic edema control and steroid reduction: Case reports demonstrate rapid symptomatic improvement within days of bevacizumab administration, particularly for spinal cord diffuse midline gliomas with significant edema 3. Two patients showed tumor regression on MRI and "drastic improvement of symptoms" with bevacizumab, allowing improved activities of daily living 3.
Radiation necrosis: If radiation necrosis develops during treatment, bevacizumab led to clinical improvement in 50% of patients and permitted steroid reduction in most cases 4.
Focal angiogenic transformation: When diffuse midline gliomas develop nodular, contrast-enhancing, or necrotic lesions indicating focal neo-angiogenesis, bevacizumab may have a therapeutic rationale 5.
Evidence Against Routine Use:
A 2022 systematic review of bevacizumab in DIPG (a subset of diffuse midline gliomas) concluded that "insufficient evidence means the role of Bevacizumab in the treatment of DIPG is unclear," though it acknowledged potential benefit in select patients 4. The review found inconsistent results across studies regarding survival, radiological response, and clinical outcomes.
Practical Treatment Algorithm
Use bevacizumab in diffuse midline gliomas when:
- At recurrence after standard radiotherapy has been completed 1
- Symptomatic progression with significant edema causing neurological deterioration 3, 6
- Development of contrast-enhancing lesions suggesting focal angiogenesis 5
- High steroid requirements that need reduction due to side effects 3, 4
- Radiation necrosis complicating treatment 4
Dosing considerations: Evidence suggests 5 mg/kg every 2 weeks may be as effective as 10 mg/kg with similar toxicity profiles and lower cost 7.
Do NOT use bevacizumab:
- As first-line therapy in newly diagnosed diffuse midline gliomas (no established benefit beyond radiotherapy) 1
- With expectation of survival benefit (use for symptom management only) 1, 8
- Beyond documented progression on bevacizumab itself 1
Critical Caveats
The EANO guidelines explicitly discourage continuing any treatment beyond confirmed progression on that same treatment, including bevacizumab 1. This is crucial—if the tumor progresses on bevacizumab, switch strategies rather than continuing.
Competing risks: Recent analysis shows bevacizumab may reduce documented radiological progression (HR 0.29) but potentially increase death before documented progression (HR 1.65), suggesting it may mask true disease progression rather than control it 8. This means MRI improvement does not necessarily translate to meaningful disease control.
Steroid interactions: Avoid long-term steroids as they are a negative prognostic factor and may interfere with treatment efficacy 1. Use bevacizumab specifically to reduce steroid dependence when possible.
Pediatric considerations: Given the lack of efficacy in pediatric high-grade glioma trials and risk of non-mandibular osteonecrosis in patients under 18 years 2, use bevacizumab in pediatric diffuse midline gliomas only for clear symptomatic benefit, not disease control.